Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 33 Years - Since 1980		THE CURRENT TIME at LC Labs is:
		Search:  Product Pages Only  Entire Site

A-3465 Alvocidib, Free Base, >99%      NEW!

Synonyms:  [CPB] [DB03496] [Flavo] [Flavopiridol] [HL-275] [HMR-1275] [L86-8275] [LS-39494] [MDL 107,826A] [LS 39494] [LS39494] [L 86-8275] [L-86-8275] [L 868275] [L868275] [HMR 1275] [HMR1275] [HL 275] [HL275] [MDL-107,826A] [MDL107,826A] [MDL 107826A] [MDL-107826A] [MDL107826A]

M.W. 401.84

C21H20ClNO5

[146426-40-6]

M.I. 14:  4094

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Alvocidib, also known as flavopiridol or HMR-1275, is a cyclin-dependent kinase (CDK) inhibitor.

• Alvocidib is a broad-spectrum inhibitor of CDKs and targets their ATP binding sites.  It promotes cell cycle arrest and apoptosis, induces differentiation, blocks transcription elongation, and inhibits angiogenesis.  Senderowicz, A.M.  "Small-molecule cyclin-dependent kinase modulators."  Oncogene 22:  6609-6620 (2003).

• Administration of flavopiridol to older (>70 years) chronic lymphocytic leukemia patients is feasible, tolerable, and has comparable efficacy to that in younger patients (<70 years).  Stephens, D.M., et al.  "Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach."  Haematologica 97:  423-427 (2012).

• Preclinical studies have shown that alvocidib induces apoptosis in both normal and malignant cells, particularly those of hematopoietic origin.  Arguello, F., et al.  "Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts."  Blood 91:  2482-2490 (1998).

• Alvocidib potentiates paclitaxel-induced apoptosis in the human gastric and breast cancer cell lines MKN-74 and MCF-7.  Motwani, M., et al.  "Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells."  Clin. Cancer Res. 5:  1876-1883 (1999).

• Alvocidib (100-200 nM) potentiates phorbol 12-myristate 13-acetate (PMA, 10 nM)-induced apoptosis in human myeloid leukemia cells U937 and HL-60.  Cartee, L., et al.  "Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways."  Mol. Pharmacol. 61:  1313-1321 (2002).

• In early clinical trials, alvocidib demonstrated limited activity in patients with gastric carcinoma and lung cancer.  Schwartz, G.K., et al.  "Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma."  J. Clin. Oncol. 19:  1985-1992 (2001).  Shapiro, G.I., et al.  "A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer."  Clin. Cancer Res. 7:  1590-1599 (2001).

• In vitro, alvocidib inhibited proliferation of human and mouse synovial fibroblasts.  In vivo, treatment with alvocidib suppressed synovial hyperplasia and joint destruction in mice with collagen-induced arthritis.  Sekine, C., et al.  "Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors."  J. Immunol. 180:  1954-1961 (2008).

• Alvocidib has potent antiviral activity in vitro againest HIV-1 and HSV-1.  Schang, L.M.  "Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication."  Biochim. Biophys. Acta. 1697:  197-209 (2004).

• Related CAS numbers:  131740-09-5 for the hydrochloride salt.

• Another CAS number previously assigned to alvocidib free base, namely 358739-39-6, has been deleted by CAS and is no longer in use.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.

** Our prices are lower than other vendors', but there is no compromise in quality.  Read how we are able to accomplish this:  Product Quality Discussion.

NOTES:
1.  The purpose of our competitor price comparison tables is to enable our visitors to compare the prices and purities of products of nominally equivalent quality, for vendors whose price and purity claims are openly available from a website or catalog (without a need for the customer to contact the vendor and request a quotation in order to obtain a price and purity for a standard product size).  However, the quality comparisons in these tables are not absolute:  although our product purities are uniformly very high and are established by careful testing of every lot in our laboratories, we cannot and do not vouch for the purities claimed by other vendors in these competitor price comparison tables.  (We do carry out occasional testing of other vendors' products -- see below --  and we have found many instances where vendors' product purities are far below their claimed levels.)  Effective April 1, 2011, our price comparison tables only include products where a purity commitment is found together with sizes and prices on at least one page of the vendor's web site.

2.  Researching and compiling sizes and prices for the >160 competitive vendors and more than 175 products is an expensive and tedious task for our small company.  Thus, we typically only perform revisions of these tables annually or less frequently.  The date and source of each competitive vendor's prices is indicated at the bottom of this page.  Obviously, we make no guarantee that competitive vendor prices will remain unchanged in the interval between our annual revisions.  We may occasionally update individual competitive vendor information and add new competitive vendors as we locate them.

3.  In some circumstances we permanently remove vendors from our price comparison tables.  Circumstances that lead to permanent removal are: 

A.  If a vendor does not honor its advertised price (ignoring small price increases) for one or more products when an order is attempted.  Example:  a vendor listed a compound at $808 for 10 grams on its website price list, but quoted $4,500 per 10 grams upon our inquiry.  That vendor has been permanently removed from our price comparison tables.

B.  If, on a product-by-product basis, our analyses of a vendor's product show purities more than a few percent below the vendor's advertised purities.  Example:  a vendor advertises a purity for 97% for a compound, but repeated elemental analyses show a minimum of 9% inorganic material present, beyond any salt counterion.  Another example: an HPLC analysis at a relevant UV detector wavelength shows 92% purity for a vendor's product for which 98% purity is claimed.  We realize of course that UV absorbances for impurities can be higher than for the main compound, but our products meet our purity commitment of typically >99% irrespective of absorbance factors for impurities, and we apply that standard to products from other vendors.

C.  Again on a product-by-product basis, if a vendor makes no purity claim for a given product, then their product is not shown on that product table.

D.  If we find that, as a pattern, several of a competitive vendor's products fail to meet their advertised purity commitments by significant margins or if a vendor does not provide standard and consistent purity claims for several of its products, then that vendor is permanently removed from all of our competitor price tables.

E.  Finally, if we determine that a vendor has provided fraudulent information on its website, in its literature or on a certificate of analysis, that vendor is permanently removed from all of our price comparison tables.

4.  IMPORTANT:  The presence of a competitive vendor entry in our price comparison tables does not necessarily mean that we have analyzed any of that vendor's products for purity; indeed, in most cases we have not.

5.  Please note:  where necessary, competitor prices are rounded to the nearest whole dollar.

To the best of our knowledge, the prices listed above for our competitors' products were correct as of the dates listed below for the sources of our annual price information update process.

Pricing Sources and Dates:  LC Labs - Current, Sigma-Aldrich - website - Jan 2013, Enzo Life Sciences - website - Jan 2013, Axxora - website - Jan 2013, Crescent Chem. - website - Mar 2013, Santa Cruz Biotech - website - Jan 2013, BioVision - website - Jan 2013, PharmBlock - website - Apr 2013, Carbone Scientific - website - Jan 2013, TCASChem Tech - website - Apr 2013, biorbyt.com - website - Jan 2013, AddexBio - website - Jan 2013, Stru Chem - website - Jan 2013, AOKBIO - website - May 2013, AbMole BioScience - website - Dec 2012, SynChem - website - Dec 2012, Medchem Express - website - Jan 2013, AdooQ BioScience - website - Jan 2013, Krackeler Scientific - website - Jan 2013, EMMX BioChemicals - website - Jan 2013, ChemScene - website - Jan 2013, Glixx Laboratories - website - Jan 2013, XcessBio - website - Mar 2013, Kinasechem - website - Apr 2013.

^† Note:  Sigma-Aldrich's product F3055, Crescent Chemical's product F3055, Krackeler Scientific's product 45-F3055, and LabLife's product F3055 are the hydrated hydrochloride salt form of this compound.  Glixx Laboratories' product GLXC-02732 and Kinasechem's product K1068 are the hydrochloride salt form of this compound.